Physician profile
Daniela Marques
NPI 1265095657
$3,360.67
in general payments reported to CMS, 2019-2025
28 companies · $76.72 in 2025
The $76.72 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $671 · 2023: $1,867 · 2024: $746 · 2025: $76.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $397.35 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $396.43 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $314.41 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $297.03 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.28 | 2022-2024 | Jardiance |
| Amgen INC. | $230.75 | 2022-2024 | Repatha, Otezla, Prolia |
| Merck Sharp & Dohme LLC | $218.76 | 2022-2024 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $179.79 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $150.23 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $125.78 | 2022-2024 | Xifaxan, Trulance |
| Abbvie INC. | $117.06 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.29 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $88.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $71.45 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $64.23 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $63.73 | 2022-2024 | Accurian, Intellis Adaptivestim |
| Corium, LLC | $44.31 | 2023 | Adlarity |
| Astellas Pharma US INC | $35.50 | 2023 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $32.64 | 2022-2023 | Accrufer |
| Ibsa Pharma INC. | $26.83 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.14 | 2022 | |
| Ironwood Pharmaceuticals, INC | $21.05 | 2023 | Linzess |
| Janssen Pharmaceuticals, INC | $18.40 | 2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $15.68 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $15.39 | 2024 | Relexxii |
| Hikma Pharmaceuticals USA | $14.54 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.34 | 2024 | Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.18 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Marques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.